Word-class speaker faculty announced for the eMarketing Summit 2008

eyeforpharmaeyeforpharma has announced their 20 world class speakers for one of the biggest and influential European online marketing and eDetailing strategy summit for the pharmaceutical industry on 15-16 May in Zurich. The conference is yet to be officially launched but in a sneak preview of the agenda Gerard Moore has announced that the following eMarketing experts will be speaking at the event.

In a statement Gerard Moore said "We are so proud to be part of this ongoing improvement of pharma's eMarketing strategies, brand awareness and success in generating top-line revenue for the industry. With the European healthcare environment producing so many new challenges and dynamic changes, sales and marketing activities in pharmaceutical companies need to really start responding to this healthcare climate change. This conference provides a perfect learning, knowledge sharing and discussion platform to overcome these challenges"

The Keynotes include:

  • Kathleen O'Nieal, Vice President, Merck Sharp and Dohme
  • Juris Ezernieks, Head of Online Communication, Pfizer
  • Christophe Ferse, Director of Global eMarketing, Bayer-Schering
  • Josefin Bond, Global eMarketing Manager, AstraZeneca
  • Bart Vannieuwenhuyse, Executive Director CRM, Janssen-Cilag
  • Len Starnes, Head of Global e-Business primary care, Bayer-Schering
  • And the rest are now available to see on the official website: http://www.eyeforpharma.com/onlinemarketing2008/

In addition, eyeforpharma proudly announce that Antwerpes, Blue Latitude and Agnitio are all major sponsors and supporters of the conference.

The 2 1/2 day conference consists of presentations, workshops, coaching clinics, networking party and pre-conference learning workshop and is seen as the leading conference and meeting place for eMarketing and eDetailing executives in the pharmaceutical industry, with over 200 delegates attending the Berlin conference in 2008. The wide range of topics at the conference include: Targeting and Segmentation, Multi-Channel Marketing, Non-Branded disease awareness campaigns, physician relationship marketing, eDetailing, Web 2.0 and New Media and how they can be used in the pharmaceutical industry to increase the effectiveness of a company's eMarketing capabilities in an ever changing and challenging healthcare environment.

eyeforpharma is offering an earlybird discount for those that register their place at the Summit early, with €300 knocked off the price of tickets to anyone registering before February 22nd. Further updates, full information on presentations and speakers, and details on other ticket options can all be found by visiting http://www.eyeforpharma.com/onlinemarketing2008/

About the eyeforpharma eMarketing Summit Europe
The eyeforpharma eMarketing Summit was established 2 years ago and is now the Europe's leading and most established eMarketing strategy conference for the pharmaceutical industry. With over 200 attendees participating in Berlin in 2007 and over 250 expected in 2008 in Zurich it is seen as the meeting and learning place for senior-level eMarketing executives from across the world to learn how they can increase the effectiveness of their online marketing and eDetailing in an ever changing and constantly challenging healthcare environment.

Find out more at http://www.eyeforpharma.com/onlinemarketing2008/

The event is organised and researched independently by eyeforpharma.

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...